Alnylam Pharmaceuticals, Inc. Share Price Sao Paulo
Equities
A1LN34
BRA1LNBDR003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.55 BRL | +78.70% | +52.86% | +51.29% |
Sales 2024 * | 1.88B 10.49B 148B | Sales 2025 * | 2.3B 12.87B 182B | Capitalization | 30.74B 172B 2,431B |
---|---|---|---|---|---|
Net income 2024 * | -455M -2.55B -35.99B | Net income 2025 * | -226M -1.26B -17.88B | EV / Sales 2024 * | 15.8 x |
Net cash position 2024 * | 1.08B 6.05B 85.5B | Net cash position 2025 * | 492M 2.75B 38.88B | EV / Sales 2025 * | 13.1 x |
P/E ratio 2024 * |
-68.1
x | P/E ratio 2025 * |
-148
x | Employees | 2,100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.58% |
Latest transcript on Alnylam Pharmaceuticals, Inc.
1 day | +78.70% | ||
1 week | +52.86% | ||
Current month | +76.37% | ||
1 month | +76.37% | ||
3 months | +86.45% | ||
6 months | +51.29% | ||
Current year | +51.29% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 18/09/16 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 56 | 12/08/19 |
Piyush Sharma
CMP | Compliance Officer | - | 20/09/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 17/12/15 |
Charles Sigal
BRD | Director/Board Member | 72 | 21/08/22 |
Margaret Hamburg
BRD | Director/Board Member | 68 | 09/01/19 |
Date | Price | Change | Volume |
---|---|---|---|
28/06/24 | 67.55 | 0.00% | 10 |
27/06/24 | 67.55 | -0.19% | 590 |
26/06/24 | 67.68 | +36.20% | 4 |
25/06/24 | 49.69 | +3.56% | 1 |
Delayed Quote Sao Paulo, June 28, 2024 at 05:21 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |
- Stock Market
- Equities
- ALNY Stock
- A1LN34 Stock